Stalicla S.A.

https://www.stalicla.com

LinkedIn: https://www.linkedin.com/company/stalicla

STALICLA is a near clinical Company developing a first in class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDDs). First focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need. In its Geneva and Barcelona units, STALICLA has assembled a world class team of experienced drug developers and computational biologists. The company is recognized as a disruptive key player in the NDD space, using its DEPIv3 innovative systems biology AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments. It is the first time that such technologies have been utilized within the field of neurodevelopment with the potential to change the direction of the specialty. In less than 3 years, the STALICLA platform has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identifying two additional subgroups. STALICLA’s first therapeutic package - STP1 - addresses this first distinct subgroup of ASD patients estimated to 1.5 - 2M people in the EU and North America. Clinical entry for STP1 is planned first half 2020. To support its platform and pipeline development, STALICLA has developed a network of top tier research and clinical partners in the US. STALICLA is currently scaling up DEPIv3 to advance new pipelines for additional groups of patients with NDDs. *

	Start	2017-01-01 established
	Industry	personalised medicine / precision medicine
	Industry 2	neurology
	Person	Durham, Lynn-Allison (Stalicla 2017– CEO + Founder)
	Person 2	Hyvelin, Jean-Marc (Stalicla 202002 COO)

	Region	Genève (Geneva) GE
	Country	Switzerland
	Street	15 Avenue de Sécheron
	City	1202 Genève GE
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2020-02-03)

		* Document for »About Section«: Stalicla S.A.. (2/3/20). "Press Release: Swiss Biotech Stalicla Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A". Geneva.

		Record changed: 2024-05-05

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Stalicla S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)